Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia

Prior treatment

• Patient on renal replacement therapy or mechanical circulatory support.

Other illness

• Disease other than HF with expected survival \<1 year.
• Patient already found to be intolerant to MRA for reasons other than hyperkalaemia or renal impairment.

Other

• Patient is participating in, or being screened for, an interventional trial, with the exception of interventional trials relating to SARS-CoV-2.

• Adult aged ≥18 years at enrolment.
• Patient diagnosed with chronic HF ≥3 months prior to signature of informed consent.
• Patient has at least 1 record of LVEF documented in patient medical record in the 24 months prior to signature of informed consent. NOTE: If the proportion of patients with HFpEF exceeds 20% of the target sample size, enrolment of patients with an LVEF ≥50% may be capped.
• Patient treated with ACEi/ARB/ARNi at enrolment.
• Patient treated with or a candidate for treatment with MRA per a relevant treatment guideline (e.g., HF, CKD, resistant hypertension) at enrolment.
• Patient at increased risk of hyperkalaemia due to one or more of the following:
  • Current hyperkalaemia (sK+ \>5.0 mEq/l) at enrolment
  • Record of documented hyperkalaemia (sK+ \>5.0 mEq/l) in the 24 months prior to signature of informed consent
  • eGFR \<45 ml/min/1.73 m2, or CKD Stage ≥3b.
• Patient judged by the Investigator to have sufficient cognitive ability to participate.
• Signed informed consent provided